Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HRH2 | P25021 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 3/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.52 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.52 |
| ▸ | MMP3 | P08254 | 3/20 | 0.51 |
| ▸ | LTA4H | P09960 | 4/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1285386 | 0.96 | MMP2 (0.61) | MAPTALDH1A1HRH2HRH1HRH3 | |
| SCHEMBL1285929 | 0.96 | MMP2 (0.61) | MAPTALDH1A1HRH2HRH1HRH3 | |
| SCHEMBL7301892 | 0.95 | MMP3 (0.57) | MAPTALDH1A1HRH2HRH1HRH3 | |
| 4-Cyanophenol SCHEMBL8993981 | 0.94 | CYSLTR2 (0.51) | MAPTALDH1A1HRH2HRH1HRH3 | |
| SCHEMBL6336869 | 0.94 | HDAC1 (0.58) | MAPTALDH1A1HRH2HRH1HRH3 | |
| SCHEMBL5522757 | 0.94 | HDAC1 (0.58) | MAPTALDH1A1HRH2HRH1HRH3 | |
| SCHEMBL15970987 | 0.92 | MMP2 (0.59) | MAPTALDH1A1HRH2HRH1HRH3 | |
| SCHEMBL7717980 | 0.92 | PPARD (0.51) | MAPTALDH1A1HRH2HRH1HRH3 | |
| SCHEMBL7717978 | 0.92 | PPARD (0.51) | MAPTALDH1A1HRH2HRH1HRH3 | |
| 4-Cyanophenol SCHEMBL8994006 | 0.90 | MMP3 (0.52) | MAPTALDH1A1HRH2HRH1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867023-B2 | Production method of polyhydroxyalkanoate from substituted fatty acid ester as raw material | CANON KABUSHIKI KAISHA (JP) | 2005-03-15 | — | — | US | claimed |
| US-20020081646-A1 | Production method of polyhydroxyalkanoate form substituted fatty acid ester as raw material | CANON KABUSHIKI KAISHA (JP) | 2002-06-27 | — | — | US | claimed |
| EP-1201763-A2 | Production method of polyhydroxyalkanoate from substituted fatty acid ester as raw material | CANON KABUSHIKI KAISHA (JP) | 2002-05-02 | — | — | EP | claimed |
| US-6867023-B2 | Production method of polyhydroxyalkanoate from substituted fatty acid ester as raw material | CANON KABUSHIKI KAISHA (JP) | 2005-03-15 | — | — | US | disclosed |
| US-20020081646-A1 | Production method of polyhydroxyalkanoate form substituted fatty acid ester as raw material | CANON KABUSHIKI KAISHA (JP) | 2002-06-27 | — | — | US | disclosed |
| EP-1201763-A2 | Production method of polyhydroxyalkanoate from substituted fatty acid ester as raw material | CANON KABUSHIKI KAISHA (JP) | 2002-05-02 | — | — | EP | disclosed |
| EP-0725059-B1 | 2,3-DIAMINOPROPIONIC ACID DERIVATIVE | SUMITOMO PHARMA (JP) | 2001-01-17 | — | — | EP | disclosed |
| US-6048854-A | ANTICOAGULANTS; ANTICANCER AGENT; WOUND HEALING AGENTS;BONE DISORDERS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-04-11 | — | — | US | disclosed |
| US-5707994-A | USEFUL AS A PLATELET AGGREGATION INHIBITOR, CANCER METASTASIS INHIBITOR, WOUND HEALING AGENT OR A BONE RESORPTION INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1998-01-13 | — | — | US | disclosed |
| CN-1138322-A | 2,3-diaminopropionic acid derivative | SUMITOMO PHARMA (JP) | 1996-12-18 | — | — | CN | disclosed |
| US-5574016-A | Peptide compound and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-11-12 | — | — | US | disclosed |
| EP-0513675-B1 | New peptide compound and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-09-11 | — | — | EP | disclosed |
| EP-0513675-A1 | New peptide compound and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020081646-A1 | Production method of polyhydroxyalkanoate form substituted fatty acid ester as raw material | FASN, FFAR1, ACADM | MAPT 4818/4885ALDH1A1 355/4885HRH2 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.